Form 4 for RLYB Rallybio Corp
Accepted 2021-08-04 00:00:00 ET · period of report 2021-08-02 · accession 0000315066-21-001650 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2021-08-04 | 2021-08-02 | RLYB | FMR LLC | See Remark 1 | C - Cnv Deriv | — | +1.69M | 1.69M | New | — |
| DI | 2021-08-04 | 2021-08-02 | RLYB | FMR LLC | See Remark 1 | C - Cnv Deriv | — | -10.79M | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-02 | C | A | 1,694,388 | — | 1,694,388 | I F-Prime Capital Partners Life Sciences Fund VI LP | — | — | (F1) On August 2, 2021 , in connection with the completion of the issuer's initial public offering, holders of Series B Preferred Units of Rallybio Holdings, LLC received an aggregate of 16,402,235 shares of common stock of Rallybio Corporation. As a result, F-Prime Capital Partners Life Sciences Fund VI LP received 1,694,388 common shares upon closing without payment of further consideration. |
| 2 | Derivative | Series B Preferred Units | 2021-08-02 | C | D | 10,789,193 | — | 0 | I F-Prime Capital Partners Life Sciences Fund VI LP | — · — to — | 1,694,388 Common Stock | (F1) On August 2, 2021 , in connection with the completion of the issuer's initial public offering, holders of Series B Preferred Units of Rallybio Holdings, LLC received an aggregate of 16,402,235 shares of common stock of Rallybio Corporation. As a result, F-Prime Capital Partners Life Sciences Fund VI LP received 1,694,388 common shares upon closing without payment of further consideration. |